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Copyright © 200? JCBN Summary Nutritional and immunological status of patients with obstructive jaundice is
usually severely altered, with high mortality rates. The n-3 polyunsaturate fatty acids (PUFA),
particularly eicosapentaenoic acid (EPA, 20:5 n-3), posess potent immunomodulatory activities.
Thus, our aim was to compare the plasma phospholipid fatty acid (FA) composition of these
patients with healthy subjects, as well as before and after 7 days preoperative supplementation
with high doses of EPA (0.9 g per day) and docosahexaenoic acid (DHA, 22:6 n-3, 0.6 g per
day). We found impaired FA status in obstructive jaundice patients, especially EPA, DHA and
PUFA, but significantly increased content of total n-3 FA, 22:5 n-3 FA and particularly EPA,
which increased more than 3 fold, after 7 days supplementation. In addition, the n6/n3 ratio
significantly decreased from 14.24 to 10.24, demonstrating severely improved plasma phospho-
lipid profile in these patients after the intervention.
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Introduction
Nutritional and immunological status of patients with
obstructive jaundice is usually severely altered [1]. For
selected patients surgery remains the only treatment option
with often complicated postoperative course. Major surgery
is followed by a period of immunosuppression that increases
the risk of morbidity and mortality due to perioperative
complications, including bleeding, wound problems, renal
and liver malfunction and particularly sepsis [2,  3].
Improving immune function during this period may signifi-
cantly reduce complications of infection [1]. The potential to
modulate the activity of the immune system by interventions
with specific nutrients (i.e. immunonutrition), has become
associated most closely with attempts to improve the clinical
course of critically ill and surgical patients [1]. The immune
function could be improved by polyunsaturate fatty acids
(PUFA), and among them, an n-3 FA from fish oil-eicosap-
entaenoic acid (EPA, 20:5 n-3) posesses the most potent
immunomodulatory activities [4].
In patients with obstructive hepatitis, malnutrition impairs
lipid digestion and uptake, partly due to bacterial degrada-
tion of bile salts and ensuing reduced micellular solubilisa-
tion. Also, bile production is decreased [5]. Since biliary
phosphatidylcholine production seems to be an important
source of intestinal essencial fatty acids (EFA) supply, an
increased degradation and a reduced bile production could
further impair the EFA status [5]. Thus, we proposed that
patients with obstructive jaundice have a poor PUFA status,
because bile acids contribute to efficient PUFA absorbtion
from the gut and because long chain PUFA (LCP) aren-3 PUFA in Obstructive Jaundice
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synthetized from their precursors, mainly in the liver. The
dietary PUFA of the n-3 series are very important for
maintance of overall health. They are rapidly incorporated
into cell membranes and profoundly influence biological
responses, from membrane fluidity, cell mobility, the forma-
tion of receptors, activation of intracellular signaling path-
ways directly or through the formation of eicosanoids, to
gene expression and cell differentiation [6]. Eicosanoids
formed from the n-3 FA are much less potent in causing
biological responses, including stimulation of cytokine
production and inflammatory reactions, than those formed
from the n-6 series [6]. The immune and inflammatory cells
contain many transcription factors including NF kappa B
(NFκB), which regulates the synthesis of cytokines IL-1,
IL-2, IL-6, TNF-α and interferon-β [7]. EPA reduces the
production of pro-inflammatory IL-1 and IL-6, as well as
TNF-α and -β in response to an inflammatory stimulus [8].
The n-3 PUFA also decrease production of arachidonic acid-
derived eicosanoids. Due to a lack of Δ6 desaturase, content
of arachidonic acid (AA) in inflammatory cells depends on
the uptake of AA synthetized in the liver from plasma
[9, 10], i.e. it depends on hepatic desaturases. The mecha-
nism of desaturase activity in obstructive jaundice is unclear,
it is not known whether bile salts affect desaturase activity
[7]. AA can be converted via an enzymatic process into
pro-inflamatory substances, especially prostaglandin E2
(PGE2), which is often increased in chronic inflammatory
conditions [10]. Fish oil, rich in EPA and docasahexaenoic
acid (DHA), inhibits production of PGE2, as well as
lymphocyte proliferation and production of IFN-γ [11].
Regarding the influence of n-3 fatty acids in immuno-
modulating processes, we tried to improve the FA profile of
preoperative patients with obstructive jaundice by seven
days preoperative supplementation of high doses n-3 FA.
The aim of this pilot study was to evaluate the plasma phos-
pholipid fatty acid composition and possible changes before
and after the supplementation.
Patients and Methods
Study design
Thirteen observed patients with obstructive jaundice (10
men, 3 women; mean age, 59 years; range, 54–68 years),
who were scheduled for major abdominal surgery, were
enrolled in this pilot study. Diagnosis of obstructive jaundice
was based on clinical and biochemical data. Before treat-
ment, total bilirubin levels were 319.2 ± 99.1 μmol/l and
direct bilirubin 66.6 ± 59.2 μmol/l, AST values 104.3 ±
56.5, ALT values167.4 ± 118.5 and gama GT levels 724.6 ±
485.4 U/l. Patients did not take fish oil supplements or lipid
lowering drugs or actively exercised before the study.
Fifteen healthy subject, sex and age matched (12 men, 3
women; mean age, 60 years; range, 54–68 years), who have
not consumed alcohol, were drawn from medical staff and
blood donors as control subjects. They had all biochemical
parameters in normal range (total bilirubin 10.8 ± 1.9 μmol/
l and direct bilirubin 2.7 ± 1.1 μmol/l, AST 20.0 ± 8.2, ALT
19.2 ± 4.3 and GGT 21.9 ± 4.5 U/l).
Patients undergoing major gastroinestinal surgery, received
n-3 soft gelatin capsules with 5 g of fish oil per day, which
contained 0.9 g EPA + 0.6 g DHA, in addition to the usual
hospital diet, composed mostly of vegetable soups without
fats and a lot of water in order to maintain optimal hydrata-
tion. A venous blood sample was drawn before and after 7
days of fish oil supplementation. Out of 13 patients, 6
abandoned the supplementation due to an urgent surgery,
whereas 7 patients completed the study. All study partici-
pants provided written informed consent which was
approved by the Ethical Review Boards of the participating
institutions in accordance with the principles of the Declara-
tion of Helsinki.
Lipid determination
Serum lipids were extracted by method of Sperry and
Brand [12] using chloroform-methanol mixture (2:1 v/v)
with 50 mg/100 ml 2,6-di-tert-butyl-4-methylphenol (BHT)
added as antioxidant. The phospholipid fraction was isolated
by one-dimensional thin-layer chromatography (TLC) in
neutral solvent system hexane : diethyl ether : acetic acid
(87:12:1, v/v/v) using Silica Gel GF plates (Merck,
Darmstadt, Germany).
Fatty acid determination
Methyl esters of phospholipid (PL) fatty acids were
prepared by method that have been reported previously [13].
FA methyl esters of isolated plasma phospholipid fractions
were separated by gas chromatography using a Varian GC
(model 3400) equipped with Rtx 2330 (60 m × 0,53 mm i.d.,
film thickness 0,2 μm (J and W Scientific Inc Bellefonte,
Folsona, CA) fused silica capilary column. The flame
ionisation detector was set at 250°C, the injection port at
220°C and the oven temperature programmed from 130°C to
190°C at the heating rate of 3°C/min. The individual fatty
acid methyl esters were identified comparing sample peak
retention times with authentic standards (Sigma Aldrich
Chemie Taufkirchen, Taufkirchen, Germany) and/or the
polyunsaturated fatty acids (PUFA)-2 standard mixtures
(Sigma Aldrich Chemie Taufkirchen).
Statistical analysis
All results are expressed as means ± SD. Normality was
tested using the Kolmogorov-Smirnov test. Since all para-
meters were normally distributed, the differences between
groups were determined by using one way ANOVA
followed by Tuckey post-hoc test, accepting an alpha levels
of significance p≤0.05.T. Popovic et al.
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Results
At the begining of this study, we compared the percent-
ages of FA in plasma phospholipids of patients with obstruc-
tive jaundice and in healthy individuals. As we expected,
preoperative patients had significantly less proportion of
EPA (20:5 n-3), DHA (22:6 n-3) and total n-3, n-6 and
PUFA than control subjects (Table 1). The percentages of
linoleic (LA, 18:2 n-6) and arachidonic acid (AA, 20:4
n-6) were significantly lower as well. On the other hand,
the percentages of short-chain FA, particularly palmitic acid
(16:0) and total SFA were higher in patients than in control
group. The n6/n3 ratio was also significantly higher in
obstructive jaundice patients.
After 7 days supplementation with high doses of EPA
(0.9 g per day) and DHA (0.6 g per day), we repeated
determination of FA in plasma PL. We found significantly
increased content of total n-3 FA and particularly EPA,
which increased more than 3 fold (Table 1). The percentage
of DHA was also higher, but the increase was not siginifi-
cant, while a significant increase in 22:5 n-3 FA was
detected as well. In addition, the n6/n3 ratio significantly
decreased from 14.24 to 10.24, demonstrating severely
improved plasma phospholipid profile in these patients
after the intervention. A representative GC chromatogram
derived from one patient before the intervention is presented
in Fig. 1.
Furthermore, the estimated desaturase acitivies are pre-
sented in Table 2. Judging by the 20:4/18:2 ratio as an index
of total Δ6 and Δ5 desaturase activities, these enzymes are
significantly more active in healthy persons than in obstruc-
tive hepatitis patients (p<0.01). On the contrary, the 18:1/
18:0 ratio as a measure of action Δ9 desaturase, was signifi-
cantly higher in the jaundice patients (p<0.05). After the
supplementation with n-3 FA, the 22:6/22:5 ratio signifi-
cantly decreased (p<0.05) in the patients. It could be ex-
plained by an increase in DPA after the supplementation
with fish oil, rather than by a decrease in Δ4 desaturase
activity.
Discussion
Many abnormalities have been described in obstructive
jaundice, but the poor outcome in these patients is still
unclear. Immune and reticuloendothelial dysfunction seem
to be important in major complications [14]. A number of
clinical intervention studies indicate that n-3 PUFA have
anti-inflammatory properties and therefore, might be useful
in the management of inflammatory and autoimmune dis-
eases [4, 15]. At sufficiently high intakes, long-chain n-3
PUFAs, as found in oily fish and fish oils, decrease the
production of inflammatory eicosanoids, cytokines, and
Table 1. Plasma phospholipid FA profile in healthy subjects and in patients with obstructive jaundice before and after
the n-3 FA supplementation.
All data are presented as a mean ± SE. Fatty acids concentrations are expressed in % of totally detected FA. SFA-
saturated fatty acids. MUFA-monounsaturated fatty acids. PUFA- polyunsaturated fatty acids. **p<0.01, ***p<0.001-
between control group and patients before treatment. #p<0.05, ###p<0.001 intergroups compared baseline to after 7 day
supplementation.
Fatty acid Control group Patients, baseline Patients, after supplementation
16:00 23.77 ± 1.13 31.6 ± 2.84*** 32.46 ± 2.40
16:1 n-7 0.24 ± 0.09 1.08 ± 0.32*** 1.23 ± 0.37
18:00 14.88 ± 1.18 13.66 ± 2.09 13.58 ± 2.74
18:1 n-9 11.85 ± 1.69 14.31 ± 2.19** 14.77 ± 1.14
18:2 n-6 28.39 ± 2.81 24.84 ± 3.43* 22.87 ± 2.03
20:3 n-6 2.71 ± 0.84 2.59 ± 1.01 2.39 ± 0.65
20:4 n-6 12.41 ± 2.20 8.81 ± 1.50*** 8.75 ± 1.43
20:5 n-3 0.41 ± 0.24 0.18 ± 0.07** 0.55 ± 0.24###
22:4 n-6 0.86 ± 0.38 0.35 ± 0.13*** 0.36 ± 0.12
22:5 n-3 0.71 ± 0.16 0.35 ± 0.1*** 0.50 ± 0.16#
22:6 n-3 3.84 ± 1.06 2.22 ± 0.74*** 2.53 ± 0.71
SFA 38.64 ± 2.12 45.26 ± 2.73*** 46.04 ± 2.29
MUFA 12.09 ± 1.68 15.39 ± 2.41*** 16.0 ± 1.27
PUFA 49.22 ± 1.92 39.34 ± 3.38*** 37.95 ± 2.65
n-6 44.27 ± 1.80 36.59 ± 3.24*** 34.38 ± 2.38
n-3 4.96 ± 1.28 2.75 ± 0.78*** 3.58 ± 0.9#
n-6/n-3 9.47 ± 2.39 14.24 ± 3.55** 10.24 ± 2.78#n-3 PUFA in Obstructive Jaundice
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reactive oxygen species and the expression of adhesion
molecules [16]. As we already mentioned above, the n-3
PUFAs particularly decrease production of arachidonic acid-
derived eicosanoids, as well as the production of the classic
inflammatory cytokines tumour necrosis factor, IL-1, IL-6
and the expression of adhesion molecules involved in
inflammatory interactions between leukocytes and endo-
thelial cells. These latter effects may occur by eicosanoid-
independent mechanisms including modulation of the acti-
vation of transcription factors involved in inflammatory
processes [15, 17]. Long-chain n-3 PUFAs also give rise to
a family of anti-inflammatory mediators termed resolvins
[17].
Considering all these reasons, in this study we evaluated
the FA profile including the n-3 status in plasma phospho-
lipid in patients with obstructive jaundice, who were waiting
for surgical intervention. All patients had significantly
impaired lipid profile compared with healthy subjects. For
instance, we found significantly lower level of two n-6 FA,
LA and AA, in jaundice patients. The decreased LA
percentage could be explained with absorption disorder in
patients with obstructive jaundice [18]. Regarding that AA
is synthetised from LA by an action of desaturase and
elongase, lower level of AA is probably a consequence of
decreased LA pool, as well as inadequate activity of
elongase and desaturase system in patients with obstructive
jaundice. Contrary to our results, Wardle et al. [14] reported
similar percentages of AA in the plasma cholesterol-esters
fraction in control subjects and in jaundice patients.
However, our pilot study clearly showed that obstructive
Fig. 1. A representative example of a GC chromatogram derived from the obstructive jaundice patient before the n-3 PUFA supple-
mentation.
Table 2. The estimated desaturase activities in control subjects and in patients with obstructive jaundice before and
after the n-3 FA supplementation.
Fatty acids ratio Control group Patients, baseline Patients, after supplementation
20:4/18:2 0.45 ± 0.11 0.36 ± 0.07* 0.38 ± 0.06
20:4/20:3 5.15 ± 2.18 3.83 ± 1.16 3.95 ± 1.18
22:6/22:5 5.53 ± 1.45 6.81 ± 2.96 5.21 ± 0.96#
18:1/18:0 0.81 ± 0.16 1.08 ± 0.27** 1.13 ± 0.22T. Popovic et al.
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jaundice patients after seven days supplementation of n-3
PUFA began the absorption of EPA and DHA and its
incorporation into plasma phospholipid composition, that
was confirmed by improved plasma PL profile in these
patients. The achieved percentages of EPA were even higher
than in healthy subjects. The rise in EPA was compensated
by a decrease in LA and with slight changes in AA in our
study, which is similar to results of Katan et al. [19]. An
increased proportion of 22:5 n-3 was also detected, although
the patients were not taken this FA as a supplement, but it
was obviously synthetised from EPA. After 7 days supple-
mentation of n-3 FA, EPA and DPA (22:5 n-3) significantly
increased, while DHA level was almost the same in plasma
PL. Despite the relatively short term of supplementation,
some authors reported higher proportion of EPA in the
cholesterol esters after only 3 days of supplementation in
healthy population. In the same study DHA concentration
was also increased but in a less degree and more unstable
than EPA, within an average of 10.3 days [19]. The weak
alteration in DHA could be explained by a longer chain of
DHA compared to EPA, or DHA maybe was not incorpo-
rated into plasma PL yet, because of too short time for
incorporation during supplementation. Supplementation of
n-3 FA, however, did not significantly affect the levels of
AST, ALT and gama GT, which showed only a slight
decrease (data not shown).
The activities of desaturase enzymes were estimated
according to the ratios between single FA. We found an
increased action of Δ9 desaturase (18:1/18:0 ratio) in
patients with obstructive jaundice. The action of Δ9
desaturase is often increased in patients with decreased
both n-3 and n-6 PUFA [20]. Regarding significantly lower
level of n-3 and n-6 PUFA in plasma of jaundice patients
compared to control group, our results are in accordance
with previously published [20]. On the contrary, 20:4/18:2
ratio suggesting total Δ6 and Δ5 desaturase activities, was
higher in healthy subjects than in our patients. One of the
reason could be decreased absorbtion of LA and AA
synthesis in obstructive jaundice which led to a lower
ratio of 20:4/18:2. In addition, desaturase activity is
probably decreased due to the liver disorder, regarding that
desaturase and elongase system, as well as PUFA synthesis,
are mainly in the liver. Although we did not investigate the
aetiology of the FA abnormalities in this study, possibilities
include malabsorbtion of essential FA and dysfunction of
hepatic FA desaturase enzymes. The direction of observed
changes is consistent with the hypothesis that FA abnormal-
ities underlie many of the changes in obstructive jaundice,
especially those in immune and reticuloendothelial function.
However, the better understanding of the relationship
between FA profile improvement and prevention against
immune dysfunction requires additional investigations.
Our results indicated the possible need of n-3 PUFA
supplementation to a regular hospital diet in patients with
obstructive jaundice before surgical treatment. We propose
that it may lead at least in part to a better immune response
and also in beneficial effect of gastroinestinal surgery. In
spite of this conclusion, we have not examined the immuno-
logical parameters so far, as well as the fact that the absorp-
tion of n-3 PUFA in these patients was happened without
participation of bile itself. Our future examinations would
address these data.
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